

# Rina M Mbofung

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9034952/publications.pdf>

Version: 2024-02-01

12  
papers

2,213  
citations

1163117

8  
h-index

1281871

11  
g-index

12  
all docs

12  
docs citations

12  
times ranked

5090  
citing authors

#	ARTICLE	IF	CITATIONS
1	Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. <i>Cancer Discovery</i> , 2016, 6, 202-216.	9.4	1,158
2	Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell Therapy. <i>Cell Metabolism</i> , 2018, 27, 977-987.e4.	16.2	398
3	BRAF Inhibition Increases Tumor Infiltration by T cells and Enhances the Antitumor Activity of Adoptive Immunotherapy in Mice. <i>Clinical Cancer Research</i> , 2013, 19, 393-403.	7.0	336
4	HSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genes. <i>Nature Communications</i> , 2017, 8, 451.	12.8	107
5	The RNA-binding Protein MEX3B Mediates Resistance to Cancer Immunotherapy by Downregulating HLA-A Expression. <i>Clinical Cancer Research</i> , 2018, 24, 3366-3376.	7.0	73
6	The Effect of Topoisomerase I Inhibitors on the Efficacy of T-Cell-Based Cancer Immunotherapy. <i>Journal of the National Cancer Institute</i> , 2018, 110, 777-786.	6.3	58
7	Anti-OX40 Antibody Directly Enhances The Function of Tumor-Reactive CD8+ T Cells and Synergizes with PI3K $\beta$ Inhibition in PTEN Loss Melanoma. <i>Clinical Cancer Research</i> , 2019, 25, 6406-6416.	7.0	35
8	Integrating genome-wide CRISPR immune screen with multi-omic clinical data reveals distinct classes of tumor intrinsic immune regulators. , 2021, 9, e001819.		19
9	Aurora kinase inhibition sensitizes melanoma cells to T-cell-mediated cytotoxicity. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1101-1113.	4.2	18
10	CpG-based immunotherapy impairs antitumor activity of BRAF inhibitors in a B-cell-dependent manner. <i>Oncogene</i> , 2017, 36, 4081-4086.	5.9	8
11	Off-the-Shelf, iPSC-Derived CAR-NK Cells Multiplexed-Engineered for the Avoidance of Allogeneic Host Immune Cell Rejection. <i>Blood</i> , 2021, 138, 2795-2795.	1.4	2
12	A Novel Stealth Strategy That Activates Adoptively Transferred Allogeneic Immune Cells and Avoids Rejection for Off-the-Shelf Cell-Based Cancer Therapy. <i>Blood</i> , 2021, 138, 4800-4800.	1.4	1